Literature DB >> 56589

Inhibition of frusemide-induced hyperreninaemia by growth-hormone release-inhibiting hormone in man.

J Rosenthal, S Raptis, F Escobar-Jimenez, E F Pfeiffer.   

Abstract

In a study of the effect of somatostatin (growth-hormone release-inhibiting hormone) on plasma-renin in healthy volunteers, plasma-renin activity was measured by radioimmunoassay after the intravenous administration of somatostatin and also during frusemide-induced hyperreninaemia. While somatostatin was being given, basal values of renin were unchanged. Injection of frusemide alone produced hyperreninaemia; but, under somatostatin, renin release was inhibited by 45%. The results indicate that somatostatin is a potent inhibitor of renin and exerts its effect independent of sodium excretion, which was unchanged under somatostatin. Conceivably, somatostatin plays an important role in the regulation of endogenous renin release.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 56589     DOI: 10.1016/s0140-6736(76)91611-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  4 in total

1.  Inhibitory effect of somatostatin on the aldosterone response to angiotensin II: in vitro studies.

Authors:  M Boscaro; C Scaroni; C R Edwards; F Mantero
Journal:  J Endocrinol Invest       Date:  1982 May-Jun       Impact factor: 4.256

2.  Hemodynamic effects of somatostatin in insulin-dependent diabetic subjects.

Authors:  D Giugliano; F Cacciapuoti; M Verza; G Rosato; M Varricchio
Journal:  Acta Diabetol Lat       Date:  1979 Oct-Dec

3.  Sequential changes in plasma renin activity and plasma catecholamines in mildly hypertensive patients during acute, furosemide-induced body-fluid loss.

Authors:  G Cannella; M D Galva; M Campanini; A M Cesura; S De Marinis; G B Picotti
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Systemic hemodynamic and renal effects of midodrine and octreotide in cirrhotic patients with ascites.

Authors:  Georgios N Kalambokis; Epameinondas V Tsianos
Journal:  J Res Med Sci       Date:  2011-12       Impact factor: 1.852

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.